日本批准Eli Lilly的阿尔茨海默氏症治疗基苏拉 治疗早期症状性阿尔茨海默氏症 Japan approves Eli Lilly's Alzheimer's treatment Kisunla for early symptomatic Alzheimer's.

Eli Lilly的阿尔茨海默症治疗是Kisunla(donanemab-azbt), 获得日本卫生部批准用于早期症状性阿尔茨海默症, 包括轻微认知障碍和轻微痴呆。 Eli Lilly's Alzheimer's treatment, Kisunla (donanemab-azbt), has received approval from Japan's Ministry of Health for use in early symptomatic Alzheimer's, including mild cognitive impairment and mild dementia. 在此之前,美国于2024年7月首次批准该公约。 This follows its initial approval in the U.S. in July 2024. Kisunla旨在减少与认知下降相联系的氨基质立体积聚,并在临床研究中显示出积极的成果。 Kisunla aims to reduce amyloid plaque buildup, which is linked to cognitive decline, and has shown positive results in clinical studies.